Dysregulation of the Transcription Factors SOX4, CBFB and SMARCC1 Correlates with Outcome of Colorectal Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2009 Jan 22

PMID 19156145

Citations 59

Authors

C L Andersen

L L Christensen

K Thorsen

T Schepeler

F B Sorensen

H W Verspaget

R Simon

M Kruhoffer

L A Aaltonen

S Laurberg

T F Orntoft

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to identify deregulated transcription factors (TFs) in colorectal cancer (CRC) and to evaluate their relation with the recurrence of stage II CRC and overall survival. Microarray-based transcript profiles of 20 normal mucosas and 424 CRC samples were used to identify 51 TFs displaying differential transcript levels between normal mucosa and CRC. For a subset of these we provide in vitro evidence that deregulation of the Wnt signalling pathway can lead to the alterations observed in tissues. Furthermore, in two independent cohorts of microsatellite-stable stage II cancers we found that high SOX4 transcript levels correlated with recurrence (HR 2.7; 95% CI, 1.2-6.0; P=0.01). Analyses of approximately 1000 stage I-III adenocarcinomas, by immunohistochemistry, revealed that patients with tumours displaying high levels of CBFB and SMARCC1 proteins had a significantly better overall survival rate (P=0.0001 and P=0.0275, respectively) than patients with low levels. Multivariate analyses revealed that a high CBFB protein level was an independent predictor of survival. In conclusion, several of the identified TFs seem to be involved in the progression of CRC.

Citing Articles

Single-cell transcriptional signature-based drug repurposing and in vitro evaluation in colorectal cancer.

Mahdi-Esferizi R, Shiasi Z, Heidari R, Najafi A, Mahmoudi I, Elahian F BMC Cancer. 2024; 24(1):371.

PMID: 38528462 PMC: 10962075. DOI: 10.1186/s12885-024-12142-8.

The RUNX/CBFβ Complex in Breast Cancer: A Conundrum of Context.

Khan A, Campbell K, Cameron E, Blyth K Cells. 2023; 12(4).

PMID: 36831308 PMC: 9953914. DOI: 10.3390/cells12040641.

Prokineticins as a Prognostic Biomarker for Low-Grade Gliomas: A Study Based on The Cancer Genome Atlas Data.

Zhong J, Xiang D, Ma X Biomed Res Int. 2022; 2022:2309339.

PMID: 35845958 PMC: 9283042. DOI: 10.1155/2022/2309339.

SMARCC1 Enters the Nucleus via KPNA2 and Plays an Oncogenic Role in Bladder Cancer.

Wei Z, Xu J, Li W, Ou L, Zhou Y, Wang Y Front Mol Biosci. 2022; 9:902220.

PMID: 35669562 PMC: 9163745. DOI: 10.3389/fmolb.2022.902220.

Using BioPAX-Parser (BiP) to enrich lists of genes or proteins with pathway data.

Agapito G, Cannataro M BMC Bioinformatics. 2021; 22(Suppl 13):376.

PMID: 34592927 PMC: 8482563. DOI: 10.1186/s12859-021-04297-z.

References

Heeboll S, Borre M, Ottosen P, Andersen C, Mansilla F, Dyrskjot L . SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation. Histol Histopathol. 2008; 23(9):1069-76. DOI: 10.14670/HH-23.1069. View

Aaboe M, Birkenkamp-Demtroder K, Wiuf C, Sorensen F, Thykjaer T, Sauter G . SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res. 2006; 66(7):3434-42. DOI: 10.1158/0008-5472.CAN-05-3456. View

Hildebrandt B, Heide I, Thiede C, Nagel S, Dieing A, Jonas S . Lack of point mutations in exons 11-23 of the retinoblastoma susceptibility gene RB-1 in liver metastases of colorectal carcinoma. Oncology. 2000; 59(4):344-6. DOI: 10.1159/000012193. View

Schepeler T, Mansilla F, Christensen L, Orntoft T, Andersen C . Clusterin expression can be modulated by changes in TCF1-mediated Wnt signaling. J Mol Signal. 2007; 2:6. PMC: 1976611. DOI: 10.1186/1750-2187-2-6. View

Cuzick J . A Wilcoxon-type test for trend. Stat Med. 1985; 4(1):87-90. DOI: 10.1002/sim.4780040112. View

Roberts C, Orkin S . The SWI/SNF complex--chromatin and cancer. Nat Rev Cancer. 2004; 4(2):133-42. DOI: 10.1038/nrc1273. View

Waterman M . Lymphoid enhancer factor/T cell factor expression in colorectal cancer. Cancer Metastasis Rev. 2004; 23(1-2):41-52. DOI: 10.1023/a:1025858928620. View

Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U . Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer. 2006; 94(1):128-35. PMC: 2361083. DOI: 10.1038/sj.bjc.6602924. View

Foster C, Falconer A, Dodson A, Norman A, Dennis N, Fletcher A . Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene. 2004; 23(35):5871-9. DOI: 10.1038/sj.onc.1207800. View

10.

Parkin D . Global cancer statistics in the year 2000. Lancet Oncol. 2002; 2(9):533-43. DOI: 10.1016/S1470-2045(01)00486-7. View

11.

Wang Y, Jatkoe T, Zhang Y, Mutch M, Talantov D, Jiang J . Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol. 2004; 22(9):1564-71. DOI: 10.1200/JCO.2004.08.186. View

12.

Thorsen K, Sorensen K, Brems-Eskildsen A, Modin C, Gaustadnes M, Hein A . Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics. 2008; 7(7):1214-24. DOI: 10.1074/mcp.M700590-MCP200. View

13.

Andersen C, Jensen J, Orntoft T . Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004; 64(15):5245-50. DOI: 10.1158/0008-5472.CAN-04-0496. View

14.

Nesbit C, Tersak J, Prochownik E . MYC oncogenes and human neoplastic disease. Oncogene. 1999; 18(19):3004-16. DOI: 10.1038/sj.onc.1202746. View

15.

Feber A, Clark J, Goodwin G, Dodson A, Smith P, Fletcher A . Amplification and overexpression of E2F3 in human bladder cancer. Oncogene. 2004; 23(8):1627-30. DOI: 10.1038/sj.onc.1207274. View

16.

Kruhoffer M, Jensen J, Laiho P, Dyrskjot L, Salovaara R, Arango D . Gene expression signatures for colorectal cancer microsatellite status and HNPCC. Br J Cancer. 2005; 92(12):2240-8. PMC: 2361815. DOI: 10.1038/sj.bjc.6602621. View

17.

Nevins J . The Rb/E2F pathway and cancer. Hum Mol Genet. 2001; 10(7):699-703. DOI: 10.1093/hmg/10.7.699. View

18.

van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A . The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell. 2002; 111(2):241-50. DOI: 10.1016/s0092-8674(02)01014-0. View

19.

Ikeda Y, Oda S, Abe T, Ohno S, Maehara Y, Sugimachi K . Features of microsatellite instability in colorectal cancer: comparison between colon and rectum. Oncology. 2001; 61(2):168-74. DOI: 10.1159/000055369. View

20.

Cooper C, Nicholson A, Foster C, Dodson A, Edwards S, Fletcher A . Nuclear overexpression of the E2F3 transcription factor in human lung cancer. Lung Cancer. 2006; 54(2):155-62. DOI: 10.1016/j.lungcan.2006.07.005. View